LIPO (Lipella Pharmaceuticals Inc) Prakiraan pendapatan perusahaan

Logo perusahaan publik Lipella Pharmaceuticals (LIPO)

Geopolitical instability and the disruption of supply chains create serious risks for Lipella Pharmaceuticals (LIPO). The company's promising sales dynamics confirm these concerns, and the value of 0.00 captures this metric. The development of bladder therapy treatments promises steady demand. Meanwhile, the company is growing organically, limiting itself only to academic partnerships for molecule testing.

LIPO - Dodolan mangsa ngarep perusahaan Lipella Pharmaceuticals ing rentang 28.04.2023 - 19.07.2025

Ringkesan rincian data analitis Lipella Pharma (LIPO)

Analisis umum perusahaan:LIPO Lipella Pharmaceuticals, Inc.
Produk merek Lipella

This indicator enables the primary screening of issuers by analyzing the trend of future cash inflows. The metric measures the volume of confirmed contracts and the dynamics of liquidity flow between assets. Monitoring the company's projected sales levels warns investors against speculative errors and missed opportunities. For Lipella Pharmaceuticals (LIPO), this figure reflects the commercialization of drugs for the treatment of rare bladder pathologies. Urologists' confidence in the safety of the brand's molecules converts directly into the growth of this fundamental metric.

Perusahaan pesaing

Prakiraan volume dodolan HLN|KVUE (Kenvue Inc) - Pendapatan mangsa ngarep perusahaan|Verona Pharma Corp - Volume dodolan mangsa ngarep perusahaan|Prakiraan volume pendapatan perusahaan MENS (Jyong Biotech Ltd)|ligand.com - Prakiraan volume dodolan|amneal.com (AMRX) - Volume dodolan mangsa ngarep perusahaan|Perrigo (PRGO) - Prakiraan pendapatan perusahaan|ALVO (Alvotech S.A.) - Prakiraan pendapatan perusahaan|Volume dodolan mangsa ngarep perusahaan LQDA|Prakiraan volume dodolan Galapagos Corp|Prakiraan pendapatan perusahaan ANI Pharma (ANIP)|Prakiraan volume dodolan MannKind Corporation (MNKD)|Prakiraan pendapatan perusahaan Amphastar Pharmaceuticals Inc AMPH|Prakiraan volume dodolan Pacira PCRX|ARS Pharmaceuticals Inc - Prakiraan volume dodolan|TBPH - Prakiraan volume dodolan|AQST (Aquestive Therapeutics) - Volume dodolan mangsa ngarep perusahaan|scPharmaceuticals, Inc. (SCPH) - Prakiraan volume dodolan|Volume dodolan mangsa ngarep perusahaan TECX|Prakiraan volume dodolan Tonix Pharma|Volume dodolan mangsa ngarep perusahaan SXTC (SXT Pharmaceuticals)|EPRX: Pendapatan sing dikarepake perusahaan|BioHarvest Sciences - Volume dodolan mangsa ngarep perusahaan|EXOZ: Prakiraan pendapatan perusahaan|ORMP - Prakiraan pendapatan perusahaan|ENTX: Prakiraan pendapatan perusahaan|HYFT: Prakiraan volume dodolan|Volume dodolan mangsa ngarep perusahaan ABVC BioPharma Inc|CPIX (Cumberland Corp) - Prakiraan volume dodolan|Prakiraan volume dodolan quantumbiopharma.com|Prakiraan volume dodolan FGEN|Volume dodolan mangsa ngarep perusahaan Telomir Pharmaceuticals, Inc. TELO|Prakiraan volume dodolan RANI (Rani Therapeutics)|SNYR (Synergy CHC Corp) - Pendapatan sing dikarepake perusahaan|RLYB: Volume dodolan mangsa ngarep perusahaan|lexariabioscience.com (LEXX) - Volume dodolan mangsa ngarep perusahaan|Pulmatrix Inc (PULM) - Prakiraan pendapatan perusahaan|PTHL: Prakiraan volume pendapatan perusahaan|APM (Aptorum Group Ltd) - Prakiraan volume dodolan|Lyra Therapeutics Inc (LYRA) - Dodolan mangsa ngarep perusahaan|Prakiraan volume dodolan IBO|Prakiraan volume pendapatan perusahaan TNFA|cbdMD, Inc. - Volume dodolan mangsa ngarep perusahaan|Pendapatan mangsa ngarep perusahaan PRFX|Altamira Therapeutics Ltd. - Prakiraan volume dodolan|Optinose (OPTN) - Volume dodolan mangsa ngarep perusahaan|Pieris (PIRS) - Prakiraan pendapatan perusahaan|Pendapatan sing dikarepake perusahaan PROC (Procaps Group S.A.)|Volume dodolan mangsa ngarep perusahaan PTPI|QLI: Pendapatan mangsa ngarep perusahaan|Prakiraan pendapatan perusahaan acelyrin.com (SLRN)|TFFP (TFF Pharma) - Pendapatan mangsa ngarep perusahaan